BC
RLMD icon

Boxer Capital’s Relmada Therapeutics RLMD Stock Holding History

Boxer Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-300,000
Closed -$11.3M – 85
2020
Q3 		$11.3M Hold
300,000
– – 0.39% 51
2020
Q2 		$13.4M Hold
300,000
– – 0.59% 41
2020
Q1 		$10.2M Hold
300,000
– – 0.7% 35
2019
Q4 		$11.7M Buy
+300,000
New +$9.12M 0.66% 35

Other funds holding RLMD

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Boxer Capital's RLMD Position: Q4 2020 in Review

Boxer Capital sold out of Relmada Therapeutics (RLMD) in Q4 2020, closing a stake of 300,000 shares — an estimated $11.3M sold.

Boxer Capital first reported a position in RLMD in Q4 2019 and held it in 4 quarters. The position peaked at $13.4M in Q2 2020. 80 funds tracked by Wall St. Rank hold RLMD as of Q4 2020.

  • Boxer Capital reported no remaining Relmada Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Boxer Capital sold 300,000 Relmada Therapeutics shares in Q4 2020, an estimated $11.3M.
  • Boxer Capital first reported a position in Relmada Therapeutics in Q4 2019 and held it in 4 quarters.
  • Boxer Capital's Relmada Therapeutics position peaked at $13.4M in Q2 2020.
  • 80 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2020.

Based on Boxer Capital's 13F filing for Q4 2020, filed 16 Feb 2021.